ClinicalTrials.gg
CompletedNCT02201953ASTRAL-3Updated Nov 16, 2018Results posted

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection

A Phase 3 interventional study of SOF/VEL and SOF in Hepatitis C Virus Infection, sponsored by Gilead Sciences. Completed at 76 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-16.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
558
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 94 studies testing sofosbuvir in Hepatitis C — 1 open to participants now, 3 under way, none of them phase 3. Sofosbuvir · Hepatitis C.

Enrollment
7th of 94
558 · median 75
Started
2014
with 10 others
Phase 3
30 of 94
none open now
Registered
28th of 94
by date
Lead sponsor
30 of 94
Gilead Sciences

Among the 94 studies testing sofosbuvir in Hepatitis C, this one is the 7th largest by enrollment, is one of 11 that started in 2014, is one of 30 in phase 3, and was the 28th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

1 of the 94 studies testing sofosbuvir in Hepatitis C is open now. Recruiting first, the newest first:

About sofosbuvir

Sofosbuvir: first FDA approval 2013 (SOVALDI), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing sofosbuvir in Hepatitis C, or all of them as a file.
02

Study summary

The primary objectives of this study are to compare the efficacy of treatment with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) for 12 weeks with that of sofosbuvir (SOF) + ribavirin (RBV) for 24 weeks and to evaluate the safety and tolerability of each treatment regimen in participants with chronic genotype 3 hepatitis C virus (HCV) infection.

03

Conditions studied

  • Hepatitis C Virus Infection

Keywords

  • Sofosbuvir
  • Velpatasvir
  • SOF/VEL
  • GS-5816
  • Hepatitis C
  • HCV
  • Cirrhosis
  • Genotype 3
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to provide written
  • ≥ 10\^4 IU/mL
  • HCV genotype 3
  • Chronic HCV infection (≥ 6 months)
  • Females of must have a negative serum pregnancy test
  • Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of

Exclusion criteria

Exclusion Criteria:

  • Current or prior history of clinically-significant illness (other than ) that may interfere with subject treatment, assessment or compliance with the protocol
  • Screening with abnormalities
  • Laboratory results outside of acceptable ranges at Screening
  • Pregnant or nursing female or male with pregnant female partner
  • Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson's disease, alfa-1 antitrypsin deficiency, cholangitis)
  • Infection with virus (HBV) or (HIV)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
558 participants (actual)

Study arms

  • Experimental
    SOF/VEL 12 Weeks

    SOF/VEL FDC for 12 weeks

    Drug: SOF/VEL

  • Experimental
    SOF+RBV 24 Weeks

    SOF+RBV for 24 weeks

    Drug: SOF · Drug: RBV

Interventions

  • DrugSOF/VEL

    Drug pages: Sofosbuvir · Velpatasvir

    400/100 mg FDC tablet administered orally once daily

    Also known as: Epclusa®, GS-7977/GS-5816

  • DrugSOF

    400 mg tablet administered orally once daily

    Also known as: Sovaldi®, GS-7977, PSI-7977

  • DrugRBV

    Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)

    SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.

    Time frame: Posttreatment Week 12

  2. Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)

    SVR4 and SVR24 are defined as HCV RNA \< LLOQ at 4 and 24 weeks following the last dose of study drug.

    Time frame: Posttreatment Weeks 4 and 24

  2. Percentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24

    Time frame: Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24

  3. Change From Baseline in HCV RNA at Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24

    Time frame: Baseline; Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24

  4. Percentage of Participants With Virologic Failure

    Virologic failure was defined as: * On-treatment virologic failure: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) * Virologic relapse: * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit.

    Time frame: Up to Posttreatment Week 24

07

Results

Posted Oct 26, 2016

Participant flow

Participants were enrolled at study sites in Australia, North America, Europe, and New Zealand. The first participant was screened on 14 July 2014. The last study visit occurred on 15 December 2015.

Participant flow — Overall Study
MilestoneSOF/VEL 12 WeeksSOF+RBV 24 Weeks
Started278280
Completed258224
Not completed2056
Withdrew: Randomized but never treated15
Withdrew: Lack of efficacy930
Withdrew: Lost to follow-up88
Withdrew: Withdrew consent25
Withdrew: Adverse event05
Withdrew: Death03

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)

SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.

Time frame:
Posttreatment Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
percentage of participantsSOF/VEL 12 WeeksSOF+RBV 24 Weeks
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)95.3 (92.1 to 97.5)80.7 (75.6 to 85.2)
Statistical analysis
  • SOF/VEL 12 Weeks vs SOF+RBV 24 Weeks · Difference in proportions: 14.4 · 95% CI 9.2 to 19.6Difference in proportions between treatment groups and associated 95% confidence intervals (CI) are calculated based on stratum-adjusted Mantel-Haenszel proportions.
  • SOF/VEL 12 Weeks vs SOF+RBV 24 Weeks · Cochran-Mantel-Haenszel · p = <0.001 (P-value was from the Cochran-Mantel-Haenszel test stratified by cirrhosis status and prior HCV treatment experience.)
PrimaryPercentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
Time frame:
Up to 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
percentage of participantsSOF/VEL 12 WeeksSOF+RBV 24 Weeks
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event03.3
SecondaryPercentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)

SVR4 and SVR24 are defined as HCV RNA \< LLOQ at 4 and 24 weeks following the last dose of study drug.

Time frame:
Posttreatment Weeks 4 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
percentage of participantsSOF/VEL 12 WeeksSOF+RBV 24 Weeks
SVR496.8 (93.9 to 98.5)82.2 (77.1 to 86.5)
SVR2495.3 (92.1 to 97.5)80.7 (75.6 to 85.2)
SecondaryPercentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24
Time frame:
Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24
percentage of participantsSOF/VEL 12 WeeksSOF+RBV 24 Weeks
Week 1 (SOF/VEL: N = 277; SOF+RBV: N = 275)18.4 (14.0 to 23.5)17.5 (13.2 to 22.5)
Week 2 (SOF/VEL: N = 276; SOF+RBV: N = 274)62.0 (55.9 to 67.7)50.0 (43.9 to 56.1)
Week 4 (SOF/VEL: N = 276; SOF+RBV: N = 272)91.7 (87.8 to 94.6)88.2 (83.8 to 91.8)
Week 6 (SOF/VEL: N = 276; SOF+RBV: N = 269)96.7 (93.9 to 98.5)98.9 (96.8 to 99.8)
Week 8 (SOF/VEL: N = 276; SOF+RBV: N = 269)99.6 (98.0 to 100.0)99.3 (97.3 to 99.9)
Week 10 (SOF/VEL: N = 276; SOF+RBV: N = 268)100.0 (98.7 to 100.0)99.3 (97.3 to 99.9)
Week 12 (SOF/VEL: N = 275; SOF+RBV: N = 265)100.0 (98.7 to 100.0)99.6 (97.9 to 100.0)
Week 16 (SOF/VEL: N = 0; SOF+RBV: N = 262)NA (NA to NA)98.9 (96.7 to 99.8)
Week 20 (SOF/VEL: N = 0; SOF+RBV: N = 260)NA (NA to NA)99.6 (97.9 to 100.0)
Week 24 (SOF/VEL: N = 0; SOF+RBV: N = 255)NA (NA to NA)100.0 (98.6 to 100.0)
SecondaryChange From Baseline in HCV RNA at Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24
Time frame:
Baseline; Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24
log10 IU/mLSOF/VEL 12 WeeksSOF+RBV 24 Weeks
Change at Wk 1 (SOF/VEL: N =272; SOF+RBV: N =268)-4.26 ± 0.644-4.16 ± 0.640
Change at Wk 2 (SOF/VEL: N =274; SOF+RBV: N =272)-4.82 ± 0.769-4.79 ± 0.702
Change at Wk 4 (SOF/VEL: N =276; SOF+RBV: N =270)-5.02 ± 0.776-5.09 ± 0.699
Change at Wk 6 (SOF/VEL: N =275; SOF+RBV: N =269)-5.06 ± 0.718-5.13 ± 0.712
Change at Wk 8 (SOF/VEL: N =276; SOF+RBV: N =269)-5.07 ± 0.728-5.13 ± 0.712
Change at Wk 10 (SOF/VEL: N =276; SOF+RBV: N =267)-5.07 ± 0.723-5.14 ± 0.710
Change at Wk 12 (SOF/VEL: N =275; SOF+RBV: N =264)-5.08 ± 0.721-5.14 ± 0.711
Change at Wk 16 (SOF/VEL: N = 0; SOF+RBV: N = 262)NA ± NA-5.11 ± 0.765
Change at Wk 20 (SOF/VEL: N = 0; SOF+RBV: N = 259)NA ± NA-5.14 ± 0.715
Change at Wk 24 (SOF/VEL: N = 0; SOF+RBV: N = 255)NA ± NA-5.14 ± 0.715
SecondaryPercentage of Participants With Virologic Failure

Virologic failure was defined as: * On-treatment virologic failure: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) * Virologic relapse: * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit.

Time frame:
Up to Posttreatment Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Virologic Failure
percentage of participantsSOF/VEL 12 WeeksSOF+RBV 24 Weeks
Percentage of Participants With Virologic Failure4.014.2

Adverse events

Collected over Up to 24 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SOF/VEL 12 Weeks—6/277 (2.2%)216/277 (78%)
SOF+RBV 24 Weeks—15/275 (5.5%)243/275 (88.4%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventSOF/VEL 12 WeeksSOF+RBV 24 Weeks
DeathGeneral disorders0/2771/275
CellulitisInfections and infestations0/2771/275
Lung infectionInfections and infestations0/2771/275
Propionibacterium infectionInfections and infestations0/2771/275
Forearm fractureInjury, poisoning and procedural complications0/2771/275
Gun shot woundInjury, poisoning and procedural complications0/2771/275
Intentional overdoseInjury, poisoning and procedural complications0/2771/275
BursitisMusculoskeletal and connective tissue disorders0/2771/275
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/2771/275
Cerebrovascular accidentNervous system disorders0/2771/275
Most frequent other events
Showing 10 of 30
Most frequent other events
EventSOF/VEL 12 WeeksSOF+RBV 24 Weeks
FatigueGeneral disorders71/277105/275
HeadacheNervous system disorders90/27790/275
InsomniaPsychiatric disorders32/27774/275
NauseaGastrointestinal disorders47/27758/275
IrritabilityPsychiatric disorders23/27740/275
CoughRespiratory, thoracic and mediastinal disorders14/27735/275
PruritusSkin and subcutaneous tissue disorders8/27735/275
NasopharyngitisInfections and infestations34/27733/275
DyspepsiaGastrointestinal disorders9/27730/275
AstheniaGeneral disorders16/27726/275

Baseline characteristics

Safety Analysis Set: participants who were randomized into the study and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)SOF/VEL 12 WeeksSOF+RBV 24 WeeksTotal
Mean49 ± 10.450 ± 10.050 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)SOF/VEL 12 WeeksSOF+RBV 24 WeeksTotal
Female107101208
Male170174344
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SOF/VEL 12 WeeksSOF+RBV 24 WeeksTotal
Hispanic or Latino111122
Not Hispanic or Latino266263529
Unknown or Not Reported011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)SOF/VEL 12 WeeksSOF+RBV 24 WeeksTotal
Black or African American314
White250239489
Asian232952
American Indian or Alaska Native134
Native Hawaiian or Pacific Islander022
Not Disclosed011
Region of Enrollment
Region of Enrollment(participants)SOF/VEL 12 WeeksSOF+RBV 24 WeeksTotal
New Zealand9817
Canada151833
United States6060120
Italy71118
United Kingdom5847105
Australia494493
France4852100
Germany313566
HCV Genotype
HCV Genotype(participants)SOF/VEL 12 WeeksSOF+RBV 24 WeeksTotal
Genotype 3 (No Confirmed Subtype)91827
Genotype 3a265250515
Genotype 3b257
Genotype 3h022
Genotype 3k101
Cirrhosis Status
Cirrhosis Status(participants)SOF/VEL 12 WeeksSOF+RBV 24 WeeksTotal
Yes8083163
No197187384
Missing055
IL28b Status
IL28b Status(participants)SOF/VEL 12 WeeksSOF+RBV 24 WeeksTotal
CC105111216
CT148133281
TT243155

3 further baseline measures are reported on the registry.

08

Study locations

76 sites
  • Los Angeles, California 90027, United States
  • Los Angeles, California 90048, United States
  • Sacramento, California, United States
  • San Diego, California, United States
  • Aurora, Colorado, United States
  • Gainesville, Florida, United States
  • Jacksonville, Florida, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • Wellington, Florida, United States
  • Marietta, Georgia, United States
  • Chicago, Illinois, United States
  • Indianapolis, Indiana, United States
  • Lutherville, Maryland, United States
  • Boston, Massachusetts, United States
  • Detroit, Michigan, United States
  • Bronx, New York, United States
  • New York, New York, United States
  • Durham, North Carolina, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Germantown, Tennessee, United States
  • San Antonio, Texas, United States
  • Norfolk, Virginia, United States
  • Richmond, Virginia, United States
  • Darlinghurst, New South Wales 2010, Australia
  • Brisbane, Queensland 4064, Australia
  • Clayton, Victoria 3168, Australia
  • Fitzroy, Melbourne, Victoria 3065, Australia
  • Melbourne, Victoria 3004, Australia
  • Fremantle, Western Australia 6010, Australia
  • Perth, Western Australia 6000, Australia
  • Camperdown, Australia
  • Calgary, Alberta T2N 4Z6, Canada
  • Edmonton, Alberta T6G 2B7, Canada
  • Vancouver, British Columbia V5Z 1M9, Canada
  • Vancouver, British Columbia V6Z 2C7, Canada
  • Ottawa, Ontario K1H 8L6, Canada
  • Montreal, Quebec H2X 0A9, Canada
  • Toronto, M5T 2S8, Canada
  • Clermont-Ferrand, 63000, France
  • Clichy, 92110, France
  • Creteil, 94000, France
  • Lille, 59037, France
  • Limoges, 87042, France
  • Lyon, 69004, France
  • Marseille, 13008, France
  • Paris, 75014, France
  • Pessac, France
  • Toulouse, 31059, France
  • Villejuif, 94804, France
  • Frankfurt am Main, Hessin 60590, Germany
  • Duesseldorf, North Rhine-Westphalia 40237, Germany
  • Hufelandstr, NRW 45122, Germany
  • Koln, NRW 50932, Germany
  • Berlin, 12157, Germany
  • Berlin, D-10969, Germany
  • Hamburg, Germany
  • Hannover, 30625, Germany
  • München, 81377, Germany
  • San Giovanni Rotondo, Foggia 71013, Italy
  • Firenze, 50012, Italy
  • Auckland, New Zealand
  • Christchurch, 8011, New Zealand
  • San Juan, Puerto Rico
  • Plymouth, Devon PL6 8DH, United Kingdom
  • Portsmouth, Hampshire PO6 3LY, United Kingdom
  • Glasgow, G12 0YN, United Kingdom
  • London, E1 4AT, United Kingdom
  • London, NW3 2PF, United Kingdom
  • London, SE5 9RS, United Kingdom
  • London, SW170QT, United Kingdom
  • London, W2 1NY, United Kingdom
  • Manchester, M8 5RB, United Kingdom
  • Nottingham, NG7 2UH, United Kingdom
  • Oxford, OX3 9DU, United Kingdom
09

References and documents

Publications

  • Asselah T, Charlton M, Feld J, Foster GR, Mcnally J, Brainard DM, et al. The ASTRAL Studies: Evaluation of SOF/GS-5816 Single Tablet Regimen for the Treatment of Genotype 1-6 HCV Infection [Poster P1332]. J Hepatol 2015;62:S855-S6.
  • Mangia, A., Roberts, SK., Pianko, S., Thompson, A at al. Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 24 Weeks in Genotype 3 HCV Infected Patients: The Randomized Controlled Phase 3 ASTRAL-3 Study. Hepatology 2015; 62: 1 (SUPPL) 338A.
  • Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourliere M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M; ASTRAL-2 Investigators; ASTRAL-3 Investigators. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015 Dec 31;373(27):2608-17. doi: 10.1056/NEJMoa1512612. Epub 2015 Nov 17. PubMed 26575258 ↗
  • Younossi ZM, Stepanova M, Feld J, Zeuzem S, Sulkowski M, Foster GR, Mangia A, Charlton M, O'Leary JG, Curry MP, Nader F, Henry L, Hunt S. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. Clin Gastroenterol Hepatol. 2017 Mar;15(3):421-430.e6. doi: 10.1016/j.cgh.2016.10.037. Epub 2016 Nov 12. PubMed 27847279 ↗

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Sep 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2014
First posted
Jul 28, 2014
Start
Jul 2014
Primary completionActual
Sep 2015
CompletionActual
Dec 2015
Results first posted
Oct 26, 2016
Last update
Nov 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02201953
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jul 28, 2014
Start date
Jul 2014
Primary completion
Sep 2015
Completion
Dec 2015
Results posted
Oct 26, 2016
Last update
Nov 16, 2018

Study contacts

John McNally, PhD
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sofosbuvir · Velpatasvir · Ribavirin

Start the discussion